Lv2
198 积分 2021-05-27 加入
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
9小时前
已完结
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
9小时前
已完结
Active biointegrated living electronics for managing inflammation
4天前
已完结
Productivity and quality improvement for a symmetric bispecific antibody through the application of intensified perfusion cell culture
5天前
已完结
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
6个月前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
7个月前
已完结
Averting inflammation by targeting the cytokine environment
7个月前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
7个月前
已完结
GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models
7个月前
已完结
GLP-1-based therapies for diabetes, obesity and beyond
7个月前
已完结
皖公网安备34019202002308
